CYBN
Cybin Inc. [CYBN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CYBN Stock Summary
Top 10 Correlated Stocks
CYBN
In the News
CYBN Financial details
Company Rating
-
Market Cap
160.93M
Income
-68.32M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
50
Optionable
No
Shortable
Yes
Earnings
26 Jun 2024
P/E
-2.64
Forward P/E
-
PEG
0.72
P/S
-
P/B
2.66
P/C
-
P/FCF
-5.1
Quick Ratio
2.36
Current Ratio
2.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.27
EPS next Y
-
EPS next Q
-
EPS this Y
-48.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
79.29%
-
-
-
-
SMA20
-9.28%
SMA50
-15.6%
SMA100
-1.24%
Inst Own
-
Inst Trans
-
ROA
-85%
ROE
-88%
ROC
-1.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.21-0.738
52W High
-
52W Low
-
RSI
34.81
Rel Volume
0.07
Avg Volume
5.57M
Volume
372.4K
Perf Week
-9.09%
Perf Month
-12.23%
Perf Quarter
-20.48%
Perf Half Y
-28.96%
-
-
-
-
Beta
0.959
-
-
Volatility
0.39%, 0.41%
Prev Close
0.15%
Price
6.6
Change
-5.58%
Company Profile
- Volume Average 5.57M
- Market Capitalization 160.93M
- Employee 50
- CEO Mr. Douglas L. Drysdale
- Headquarters Toronto,ON,CA
- IPO Date 2019-09-13
-
Website
https://www.cybin.com 
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
